School of Medicine
Showing 71-80 of 247 Results
-
Paul Heidenreich, MD
Professor of Medicine (Cardiovascular)
On Partial Leave from 05/01/2026 To 06/30/2026Current Research and Scholarly InterestsMy research interests include
1) The cost-effectiveness of new cardiovascular technologies.
Example: tests to screen asymptomatic patients for left ventricular systolic dysfunction.
2) Interventions to improve the quality of care of patients with heart disease. Examples: include clinical reminders and home monitoring.
3) Outcomes research using existing clinical and administrative datasets.
4) Use of echocardiography to predict prognosis (e.g. diastolic dysfunction). -
Benjamin Davies Horne
Adjunct Clinical Associate Professor, Medicine - Cardiovascular Medicine
BioDr. Benjamin Horne is an Adjunct Clinical Associate Professor who is based at the Intermountain Medical Center Heart Institute in Salt Lake City, UT, where he serves as the Director of Cardiovascular and Genetic Epidemiology. His doctoral training (PhD) in genetic epidemiology was completed at the University of Utah and he holds masters degrees in public health and in biostatistics. Dr. Horne is a fellow of the American Heart Association, a fellow of the American College of Cardiology, and a member of the American Society of Human Genetics. Dr. Horne’s research focuses on population health and precision medicine, including evaluating the genetic epidemiology of heart diseases, developing and implementing clinical decision tools for personalizing medical care, discovering the human health effects of intermittent fasting, and studying the influences of air pollution on major adverse health events.
-
Stephanie Hsiao, MD
Clinical Assistant Professor, Medicine - Cardiovascular Medicine
BioDr. Stephanie Hsiao is a clinical assistant professor at Stanford Medicine and a full-time advanced heart failure/transplant cardiologist at the Palo Alto VA. She is the associate program director of the Stanford Cardiology Fellowship and the site director of Palo Alto VA. She grew up in Taipei, Taiwan. She attended undergraduate at UC Berkeley and obtained her Master’s degree in Pharmacology at Cambridge University in the UK. She obtained her M.D. from UC San Francisco. She completed her Internal Medicine residency and General Cardiology fellowship at the California Pacific Medical Center in San Francisco, where she served as the chief resident and chief cardiology fellow. She completed her advanced heart failure/transplant cardiology fellowship at Stanford in June 2022 and joined the Stanford Faculty soon after. She has a strong interest in medical education and quality improvement. Her clinical interests include HF outreach in the VA health care systems, cardiology fellowship curriculum design/development and humanism in medicine. Her research interests include multi-organ transplantations, advanced HF therapies for the underserved and CardioPalliative integration. She plans to lead a career in medical education and quality improvement to deliver exceptional and equitable care for patients needing advanced HF therapies.
-
Jiaqi Hu
Postdoctoral Scholar, Cardiovascular Medicine
BioJiaqi Hu is a Postdoctoral Scholar at Stanford University, supervised by Drs. Tim Assimes and Shoa Clarke. She received her PhD in Chronic Disease Epidemiology from the Yale School of Public Health in 2026 and her Bachelor of Arts degree from Peking University in 2021. Her research focuses on identifying genetic variants underlying complex diseases, applying polygenic scores for disease risk prediction and subtype identification, and integrating genetic, environmental, and clinical data to improve individual-level risk stratification.
-
Hirotaka Ieki
Postdoctoral Scholar, Cardiovascular Medicine
BioCardiologist in Japan.
Research interest: precision medicine in cardiovascular disease. Genomics, Exposomics. -
Gentaro Ikeda
Instructor, Medicine - Cardiovascular Medicine
BioDr. Ikeda is a physician-scientist who develops innovative diagnostic and therapeutic modalities for patients with cardiovascular disease. Based on his clinical experience as a cardiologist, he has become aware of major clinical shortcomings, specifically in the current pharmaceutical therapies for myocardial infarction (MI) and chronic heart failure (HF). Some evidence-based drug therapies, including β-blockers, ivabradine, and renin-angiotensin-aldosterone antagonists are difficult to apply to critical patients due to adverse side effects. Drugs that have shown efficacy in basic animal experiments have failed to show significant benefits in clinical trials. To address these problems, he moved to academia to conduct translational research. During his graduate training in the Egashira Lab, he focused on drug delivery systems (DDS) that target mitochondria in animal models of MI. He obtained advanced skills in molecular biology, mitochondrial bioenergetics, and animal surgery. He realized the importance of translational research and the great potential of DDS to overcome many clinical problems. He developed nanoparticle-mediated DDS containing cyclosporine for the treatment of patients with MI. He published a first-author paper and received academic awards for his novel science. Since becoming a postdoctoral fellow in the Yang Lab, he has continued to build upon his previous training in translational research. He is currently developing an innovative therapy, namely, extracellular vesicles-mediated mitochondrial transfer for mitochondria-related diseases such as heart failure and mitochondrial disease.
